Postgenomics of Neisseria meningitidis for vaccines development.
Meningococcal disease is a global problem. Multivalent (A, C, Y, W135) conjugate vaccines have been developed and licensed; however, an effective vaccine against serogroup B has not yet become available. Outer membrane vesicle (OMV) vaccines have been used to disrupt serogroup B epidemics and outbreaks. Postgenomic technologies have been useful in aiding the discovery of new protein vaccine candidates. Moreover, proteomic technologies enable large-scale identification of membrane and surface-associated proteins, and provide suitable methods to characterize and standardize the antigen composition of OMV-based vaccines.
Bernardini
Giulia
G
Università degli Studi di Siena, Dipartimento di Biologia Molecolare, via Fiorentina 1, 53100 Siena, Italy. bernardini@unisi.it
Braconi
Daniela
D
Martelli
Paola
P
Santucci
Annalisa
A
D023281:Genomics / Q000379:methods*; D006801:Humans; D008589:Meningococcal Infections / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000235:genetics / Q000276:immunology*; D009345:Neisseria meningitidis / Q000235:genetics* / Q000276:immunology*; D040901:Proteomics
D022401:Meningococcal Vaccines